Researchers demonstrate that non-viral gene therapy can delay the onset of some forms of retinal degeneration and preserve vision, according to a new study. The researchers developed nanoparticles to deliver therapeutic genes to the retina and found that treated mice temporarily retained more eyesight than controls. "Our work shows that...

Intravitreal injections performed with a 30-gauge needle more often result in significant elevations of intraocular pressure (IOP) requiring extraction of fluid from the anterior chamber of the eye to rapidly lower the pressure, a procedure known as paracentesis, than when injections are performed using a 27-guage needle. Elevation of IOP is a...

Tunneled scleral injection technique causes greater short-term intraocular pressure (IOP) elevation following intravitreal Lucentis (ranibizumab). Elevation of IOP is a risk factor for glaucoma. IOP reflects a balance between the rate that fluid flows into the eye and the rate that it exits the eye. If inflow increases or outflow decreases,...

Intravitreal injection of Lucentis (ranibizumab) does not produce a therapeutic effect in the fellow eye of patients with bilateral exudative age-related macular degeneration (AMD), according to a new study. In patients with exudative AMD, intravitreal anti-vascular endothelial growth factor (VEGF) therapy can lead to stabilization and even...

Anterior chamber paracentesis prior to intravitreal Macugen (pegaptanib) injection prevents elevation of intraocular pressure (IOP) elevation following injection. Elevation of IOP is a risk factor for glaucoma. IOP reflects a balance between the rate that fluid flows into the eye and the rate that it exits the eye. If inflow increases or...

The rate of intravitreal injections in Ontario grew 8-fold between 2000 and 2008, according to a new study. Intravitreal injections of VEGF inhibitors surged between 2005 and 2007, with a small number of ophthalmologists performing more than half the injections. Using a population-based retrospective design, we studied monthly fee claims for...

Researchers demonstrate the feasibility of Macroesis, a propeitarity alternating electical current drug delivery system, for the transcleral delivery of Lucentis (ranibizumab) and triamcinolone acetonide in rabbit eyes. The current method of delivery of ocular therapeutics is through injections in the eye. These injections have been associated...

Traditionally, ocular medications have been delivered through eye drops, intravitreal injections and systemic means. Now, various implants are being developed to deliver drugs for numerous indications. The main impetus for drug-eluting devices, especially in glaucoma, is patient noncompliance with dosing protocols, Steven D. Vold, MD, said....

Iluvien for diabetic macular edema significantly improved visual acuity in two phase 3 pivotal clinical trials, manufacturer pSivida announced in a press release. Alimera Sciences, pSivida's collaborative partner, plans to submit a new drug application (NDA) to the U.S. Food and Drug Administration in the second quarter of 2010, according to...

A combined age-related macular degeneration solution and drug delivery system showed promising results in a phase 1b clinical trial, manufacturers MacuCLEAR and Mystic Pharmaceuticals announced. The two firms formed a partnership to conduct clinical trials of the drug and delivery system. Trial results showed that MacuCLEAR's MC-1101, a...